BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 1412163)

  • 1. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
    Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D; Lu HR; Lijnen HR; Nelles L; Stassen JM
    Circulation; 1991 Sep; 84(3):1216-34. PubMed ID: 1909220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase.
    Holvoet P; Laroche Y; Stassen JM; Lijnen HR; Van Hoef B; De Cock F; Van Houtven A; Gansemans Y; Matthyssens G; Collen D
    Blood; 1993 Feb; 81(3):696-703. PubMed ID: 8427962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolytic and pharmacokinetic properties of a conjugate of recombinant single-chain urokinase-type plasminogen activator with a monoclonal antibody specific for cross-linked fibrin in a baboon venous thrombosis model.
    Collen D; Dewerchin M; Rapold HJ; Lijnen HR; Stassen JM
    Circulation; 1990 Nov; 82(5):1744-53. PubMed ID: 2121385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding.
    Jiao J; Yu M; Ru B
    Biochim Biophys Acta; 2001 Apr; 1546(2):399-405. PubMed ID: 11295444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D; Stassen JM; De Cock F
    Thromb Haemost; 1987 Oct; 58(3):943-6. PubMed ID: 3124288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fibrin-targeting on clot lysis with urokinase-type plasminogen activator.
    Lijnen HR; Dewerchin M; De Cock F; Collen D
    Thromb Res; 1990 Feb; 57(3):333-42. PubMed ID: 2107593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA.
    Declerck PJ; Van Keer L; Verstreken M; Collen D
    Thromb Haemost; 1992 Jan; 67(1):95-100. PubMed ID: 1377417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase.
    Holvoet P; Laroche Y; Lijnen HR; Van Cauwenberge R; Demarsin E; Brouwers E; Matthyssens G; Collen D
    J Biol Chem; 1991 Oct; 266(29):19717-24. PubMed ID: 1918077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y; Scully MF; Ellis V; Kakkar VV
    Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
    Stump DC; Stassen JM; Demarsin E; Collen D
    Blood; 1987 Feb; 69(2):592-6. PubMed ID: 3099862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolytic and pharmacokinetic properties of an immunoconjugate of single-chain urokinase-type plasminogen activator (u-PA) and a bispecific monoclonal antibody against fibrin and against u-PA in baboons.
    Imura Y; Stassen JM; Kurokawa T; Iwasa S; Lijnen HR; Collen D
    Blood; 1992 May; 79(9):2322-9. PubMed ID: 1571545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits.
    Agnelli G; Pascucci C; Colucci M; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1992 Sep; 68(3):331-5. PubMed ID: 1440500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM; Dosne AM; Kher A; Samama M
    Thromb Haemost; 1989 Nov; 62(3):923-6. PubMed ID: 2556812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrin-specific thrombolytic agents.
    Collen D
    Ann Biol Clin (Paris); 1988; 46(3):195-200. PubMed ID: 3044205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.